Optimizing therapy for myeloid disorders of Down syndrome

British Journal of Haematology

Volumn 131, Issue 1, 2005, Pages 3-7

  Webb, David K H ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Down syndrome; Myeloid leukaemia of Down syndrome; Therapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTARABINE; HEMOGLOBIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1;

ACUTE GRANULOCYTIC LEUKEMIA; ASCITES; BONE MARROW; CANCER CHEMOTHERAPY; CANCER RISK; CELL LINEAGE; CHEMOSENSITIVITY; CLINICAL FEATURE; CYTOGENETICS; DEATH; DOWN SYNDROME; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; ERYTHROCYTE COUNT; ERYTHROID CELL; GENE FUNCTION; GENE MUTATION; GROUPS BY AGE; HEPATOSPLENOMEGALY; HUMAN; INFECTION; JAUNDICE; LEUKOCYTE COUNT; LEUKOCYTOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; LOW DRUG DOSE; MEGAKARYOBLAST; MEGAKARYOCYTE; MUCOSA INFLAMMATION; MYELODYSPLASIA; MYELOID LEUKEMIA; MYELOPOIESIS; NEUTROPHIL COUNT; ONSET AGE; PEDIATRICS; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVIEW; SKIN INFILTRATE; ACUTE DISEASE; DRUG ADMINISTRATION; IMMUNOLOGY; INFANT; NEURAL TUBE DEFECT; PRESCHOOL CHILD;

ACUTE DISEASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD, PRESCHOOL; DOWN SYNDROME; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; LEUKEMIA, MYELOID; MEGAKARYOCYTES; NEURAL TUBE DEFECTS;

EID: 27744567768     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05700.x     Document Type: Review

References (41)

1. Abe K. Kajii T. Niikawa N. ( 1989) Disomic homozygosity in 21-trisomic cells: a mechanism responsible for transient myeloproliferative syndrome. Human Genetics, 82, 313 316.
2. Ahmed M. Sterberg A. Hall G. Thomas A. Smith O. O'Marcaigh A. Wynn R. Stevens R. Addison M. King D. Stewart B. Gibson B. Roberts I. Vyas P. ( 2004) Natural history of GATA-1 mutations in Down syndrome. Blood, 105, 2480 2486.
3. Al-Kasim F. Doyle J.J. Massey G.V. Weinstein H.J. Zipursky A. ( 2002) Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group study. Journal of Pediatric Hematology and Oncology, 24, 9 13.
4. Belkov V.M. Krynetski E.Y. Schuetz J.D. Yanishevski Y. Masson E. Mathew S. Raimondi S. Pui C.H. Relling M.V. Evans W.E. ( 1999) Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood, 93, 1643 1650.
5. Craze J.L. Harrison G. Wheatley K. Hann I.M. Chessells J.M. ( 1999) Improved outcome of acute myeloid leukaemia in Down's syndrome. Archives of Disease in Childhood, 81, 32 37.
6. Creutzig U. Ritter J. Vormoor J. Ludwig W.D. Niemeyer C. Reinisch I. Stollmann-Gibbels B. Zimmermann M. Harbott J. ( 1996) Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia, 10, 1677 1686.
7. Creutzig U. Zimmermann M. Reinhardt D. Dworzak M. Stary J. Lehrnbecher T. ( 2004) Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukaemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. Journal of Clinical Oncology, 22, 4384 4393.
8. Creutzig U. Reinhardt D. Diekamp S. Dworzak M. Stary J. Zimmermann M. ( 2005) AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia, 2005 May 26 (epub ahead of print). doi 10.1038/sj.leu.2403814 44.
9. Gamis A.S. Woods W.G. Alonzo T.A. Buxton A. Lange B. Barnard D.R. Gold S. Smith F.O. ( 2003) Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. Journal of Clinical Oncology, 21, 3415 3422.
10. Gurbuxani S. Vyas P. Crispino J.D. ( 2004) Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood, 103, 399 406.
11. Hasle H. Clemmensen I.H. Mikkelsen M. ( 2000) Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet, 355, 165 169.
12. Hasle H. Niemeyer C.M. Chessells J.M. Baumann I. Bennett J.M. Kerndrup G. Head D.R. ( 2003) A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia, 17, 277 282.
13. Hattori H. Matsuzaki A. Suminoe A. Ihara K. Nakayama H. Hara T. ( 2001) High expression of platelet-derived growth factor and transforming growth factor-beta 1 in blast cells from patients with Down Syndrome suffering from transient myeloproliferative disorder and organ fibrosis. British Journal of Haematology, 115, 472 475.
14. Honda F. Punnett H.H. Charney E. Miller G. Thiede H.A. ( 1964) Serial cytogenetic and hematologic studies on a Mongol with trisomy-21 and acute congenital leukemia. Journal of Pediatrics, 65, 880 887.
15. Huret J.L. Leonard C. ( 1997) Chromosome 21 and platelets: a gene dosage effect Clinical Genetics, 51, 140 141.
16. Kojima S. Matsuyama T. Sato T. Horibe K. Konishi S. Tsuchida M. Hayashi Y. Kigasawa H. Akiyama Y. Okamura J. Nakahata T. Bessho E. Eguchi M. Nakazawa S. Ueda R. ( 1990) Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction. Blood, 76, 2348 2353.
17. Kojima S. Kato K. Matsuyama T. Yoshikawa T. Horibe K. ( 1993) Favourable treatment outcome in children with acute myeloid leukemia and Down syndrome. Blood, 81, 3164 3165.
18. Kounami S. Aoyagi N. Tsuno H. Suzuki H. Kitano N. Koike M. ( 1997) Additional chromosome abnormalities in transient abnormal myelopoiesis in Down's syndrome patients. Acta Haematologica, 98, 109 112.
19. Krivit W. Good R.A. ( 1957) Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey. American Journal of Disease in Childhood, 94, 289 293.
20. Lange B.J. Kobrinsky N. Barnard D.R. Arthur D.C. Buckley J.D. Howells W.B. Gold S. Sanders J. Neudorf S. Smith F.O. Woods W.G. ( 1998) Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood, 91, 608 615.
21. Levitt G.A. Stiller C.A. Chessells J.M. ( 1990) Prognosis of Down's syndrome with acute leukaemia. Archives of Disease in Childhood, 65, 212 216.
22. Lie S.O. Jonmundsson G. Mellander L. Siimes M.A. Yssing M. Gustafsson G. ( 1996) A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). British Journal of Haematology, 94, 82 88.
23. Ravindranath Y. Abella E. Krischer J.P. Wiley J. Inoue S. Harris M. Chauvenet A. Alvarado C.S. Dubowy R. Ritchey A.K. Land V. Steuber C.P. Weinstein H. ( 1992) Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood, 80, 2210 2214.
24. Rogers P.C. Kalousek D.K. Denegri J.F. Thomas J.W. Baker M.A. ( 1983) Neonate with Down's syndrome and transient congenital leukemia. American Journal of Pediatric Hematology and Oncology, 5, 59 64.
25. Rubin C.M. Mick R. Johnson F.L. ( 1996) Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: toxicity and outcome. Bone Marrow Transplantation, 18, 533 540.
26. Song W.J. Sullivan M.G. Legare R.D. Hutchings S. Tan X. Kufrin D. Ratajczak J. Resende I.C. Haworth C. Hock R. Loh M. Felix C. Roy D.C. Busque L. Kurnit D. Willman C. Gewirtz A.M. Speck N.A. Bushweller J.H. Li F.P. Gardiner K. Poncz M. Maris J.M. Gilliland D.G. ( 1999) Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Naure Genetics, 23, 166 175.
27. Taub J.W. Ge Y. ( 2005) Down syndrome, drug metabolism and chromosome 21. Pediatric Blood and Cancer, 44, 33 39.
28. Taub J.W. Matherly L.H. Stout M.L. Buck S.A. Gurney J.G. Ravindranath Y. ( 1996) Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood, 87, 3395 3403.
29. Taub J.W. Huang X. Matherly L.H. Stout M.L. Buck S.A. Massey G.V. Becton D.L. Chang M.N. Weinstein H.J. Ravindranath Y. ( 1999) Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood, 94, 1393 1400.
30. Tschernia G. Lejeune F. Bocacara J.F. Denavit M.F. Dommergues J.P. Bernaudin F. ( 1996) Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: treatment with low dose arabinosyl cytosine. Journal of Pediatric Hematology and Oncology, 18, 59 62.
31. Webb D.K. Harrison G. Stevens R.F. Gibson B.G. Hann I.M. Wheatley K. ( 2001) Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood, 98, 1714 1720.
32. Wechsler J. Greene M. McDevitt M. Anastasi J. Karp J.E. LeBeau M.M. Crispino J.D. ( 2002). Acquired mutations in GATA 1 in the megakaryoblastic leukemia of Down syndrome. Nature Genetics, 32, 148 152.
33. Zeller B. Gustafsson G. Forestier E. Abrahamsson J. Clausen N. Heldrup J. Hovi L. Jonmundsson G. Lie S.O. Glomstein A. Hasle H. ( 2005) Acute leukaemia in children with Down syndrome: a population-based Nordic study. British Journal of Haematology, 128, 797 804.
34. Zipursky A. ( 1996) The treatment of children with acute megakaryoblastic leukemia who have Down's syndrome. Journal of Pediatric Hematology and Oncology, 18, 10 12.
35. Zipursky A. Poon A. Doyle J. ( 1992) Leukemia in Down syndrome: a review. Pediatric Hematology and Oncology, 9, 139 149.
36. Zipursky A. Thorner P. De Harven E. Christensen H. Doyle J. ( 1994) Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leukemia Research, 18, 163 171.
37. Zipursky A. Rose T. Skidmore M. Thorner P. Doyle J. ( 1996) Hydrops fetalis and neonatal leukemia in Down syndrome. Pediatic Hematology Oncology, 13, 81 87.
38. Zipursky A. Brown E. Christensen H. Sutherland R. Doyle J. ( 1997) Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Seminars in Perinatology, 21, 97 101.
39. Zipursky A. Brown E.J. Christensen H. Doyle J. ( 1999) Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome. Clinical and Laboratory Medicine, 19, 157 167.
40. Zubizarreta P. Felice M.S. Alfaro E. Fraquelli L. Casak S. Quinteros R. Cygler A. Gallego M. Perez L.E. Sackmann-Muriel F. ( 1998) Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy. Leukemia Research, 22, 465 472.
41. Zwaan C.M. Kaspers G.J. Pieters R. Hahlen K. Janka-Schaub G.E. van Zantwijk C.H. Huismans D.R. de Vries E. Rots M.G. Peters G.J. Jansen G. Creutzig U. Veerman A.J. ( 2002) Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood, 99, 245 251.